Holoendemic malaria exposure is associated with altered epstein-barr virus-specific CD8+ T-cell differentiation

Journal of Virology

Volumn 87, Issue 3, 2013, Pages 1779-1788

  Chattopadhyay, Pratip K ^a   Chelimo, Kiprotich ^b   Embury, Paula B ^c   Mulama, David H ^b   Sumba, Peter Odada ^b   Gostick, Emma ^d   Ladell, Kristin ^d   Brodie, Tess M ^a   Vulule, John ^b   Roederer, Mario ^a   Moormann, Ann M ^e   Price, David A ^a,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD57 ANTIGEN; CHEMOKINE RECEPTOR CCR7; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 3C; HLA A ANTIGEN; INTERLEUKIN 7 RECEPTOR; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BURKITT LYMPHOMA; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHILD; DISEASE ASSOCIATION; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; IMMUNOPHENOTYPING; LYMPHOCYTE DIFFERENTIATION; MALARIA FALCIPARUM; MEMORY T LYMPHOCYTE; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE SUBPOPULATION;

AFRICA; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; COINFECTION; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; T-LYMPHOCYTE SUBSETS;

EID: 84873021564     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02158-12     Document Type: Article

References (54)

1. Burkitt D. 1958. A sarcoma involving the jaws in African children. Br. J. Surg. 46:218-223.
2. Haddow AJ. 1964. Age incidence in Burkitt's lymphoma syndrome. East Afr. Med. J. 41:1-6.
3. Mwanda OW, Rochford R, Moormann AM, Macneil A, Whalen C, Wilson ML. 2004. Burkitt's lymphoma in Kenya: geographical, age, gender and ethnic distribution. East Afr. Med. J. 8:S68-S77.
4. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. 2008. Part I: cancer in indigenous Africans-burden, distribution, and trends. Lancet Oncol. 9:683-692.
5. Epstein MA, Achong BG, Barr YM. 1964. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet i:702-703.
6. Pagano JS. 1999. Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc. Assoc. Am. Phys. 111:573-580.
7. Thorley-Lawson DA, Allday MJ. 2008. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat. Rev. Microbiol. 6:913-924.
8. Dalldorf G. 1962. Lymphomas of African children with different forms or environmental influences. JAMA 181:1026-1028.
9. Kafuko GW, Burkitt DP. 1970. Burkitt's lymphoma and malaria. Int. J. Cancer 6:1-9.
10. Rainey JJ, Mwanda WO, Wairiumu P, Moormann AM, Wilson ML, Rochford R. 2007. Spatial distribution of Burkitt's lymphoma in Kenya and association with malaria risk. Trop. Med. Int. Health 12:936-943.
11. de The G, Day NE, Geser A, Lavoue MF, Ho JH, Simons MJ, Sohier R, Tukei P, Vonka V, Zavadova H. 1975. Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study-a review. IARC Sci. Publ. 11(Pt 2):3-16.
12. Henle G, Henle W, Clifford P, Diehl V, Kafuko GW, Kirya BG, Klein G, Morrow RH, Munube GM, Pike P, Tukei PM, Ziegler JL. 1969. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J. Natl. Cancer Inst. 43:1147-1157.
13. Hislop AD, Taylor GS, Sauce D, Rickinson AB. 2007. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25:587-617.
14. Khanna R, Burrows SR. 2000. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 54:19-48.
15. Rickinson AB, Moss DJ. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405-431.
16. Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF. 2000. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood 95:241-248.
17. Hislop AD, Gudgeon NH, Callan MF, Fazou C, Hasegawa H, Salmon M, Rickinson AB. 2001. EBV-specific CD8+T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J. Immunol. 167:2019-2029.
18. Baird JK, Snow RW. 2007. Acquired immunity in a holoendemic setting of Plasmodium falciparum and P. vivax malaria. Am. J. Trop. Med. Hyg. 76:995-996.
19. ter Kuile FO, Terlouw DJ, Kariuki SK, Phillips-Howard PA, Mirel LB, Hawley WA, Friedman JF, Shi YP, Kolczak MS, Lal AA, Vulule JM, Nahlen BL. 2003. Impact of permethrin-treated bed nets on malaria, anemia, and growth in infants in an area of intense perennial malaria transmission in western Kenya. Am. J. Trop. Med. Hyg. 68:68-77.
20. Good MF, Doolan DL. 2010. Malaria vaccine design: immunological considerations. Immunity 33:555-566.
21. Moss DJ, Burrows SR, Castelino DJ, Kane RG, Pope JH, Rickinson AB, Alpers MP, Heywood PF. 1983. A comparison of Epstein-Barr virusspecific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int. J. Cancer 31:727-732.
22. Whittle HC, Brown J, Marsh K, Greenwood BM, Seidelin P, Tighe H, Wedderburn L. 1984. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature 312:449-450.
23. Moormann AM, Chelimo K, Sumba PO, Tisch DJ, Rochford R, Kazura JW. 2007. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J. Infect. Dis. 195:799-808.
24. Donati D, Espmark E, Kironde F, Mbidde EK, Kamya M, Lundkvist A, Wahlgren M, Bejarano MT, Falk KI. 2006. Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J. Infect. Dis. 193:971-977.
25. Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, Kazura J, Rochford R. 2005. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J. Infect. Dis. 191:1233-1238.
26. Klein E, Klein G, Levin PH. 1976. Immunological control of human lymphoma: discussion. Cancer Res. 36:724-727.
27. Donati D, Zhang LP, Chene A, Chen Q, Flick K, Nystrom M, Wahlgren M, Bejarano MT. 2004. Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infect. Immun. 72:5412-5418.
28. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P. 1982. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. U. S. A. 79:7837-7841.
29. Moormann AM, Snider CJ, Chelimo K. 2011. The company malaria keeps: how co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma. Curr. Opin. Infect. Dis. 24:435-441.
30. Rochford R, Cannon MJ, Moormann AM. 2005. Endemic Burkitt's lymphoma: a polymicrobial disease? Nat. Rev. Microbiol. 3:182-187.
31. Roederer M, Moore W, Treister A, Hardy RR, Herzenberg LA. 2001. Probability binning comparison: a metric for quantitating multivariate distribution differences. Cytometry 45:47-55.
32. Roederer M, Hardy RR. 2001. Frequency difference gating: a multivariate method for identifying subsets that differ between samples. Cytometry 45:56-64.
33. John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, Min XM, Kazura JW. 2008. Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J. Infect. Dis. 197:519-526.
34. Cao K, Moormann AM, Lyke KE, Masaberg C, Sumba OP, Doumbo OK, Koech D, Lancaster A, Nelson M, Meyer D, Single R, Hartzman RJ, Plowe CV, Kazura J, Mann DL, Sztein MB, Thomson G, Fernandez-Vina MA. 2004. Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens 63:293-325.
35. Price DA, Brenchley JM, Ruff LE, Betts MR, Hill BJ, Roederer M, Koup RA, Migueles SA, Gostick E, Wooldridge L, Sewell AK, Connors M, Douek DC. 2005. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J. Exp. Med. 202: 1349-1361.
36. Chattopadhyay PK, Roederer M, Price DA. 2010. OMIP-002: Phenotypic analysis of specific human CD8+T-cells using peptide-MHC class I multimers for any of four epitopes. Cytometry A 77:821-822.
37. Bender R, Lange S. 1999. Multiple test procedures other than Bonferroni's deserve wider use. Br. Med. J. 318:600-601.
38. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. 2003. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101:2711-2720.
39. Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, Roederer M, De Rosa SC. 2009. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J. Leukoc. Biol. 85: 88-97.
40. Chelimo K, Embury PB, Sumba PO, Vulule J, Ofulla AV, Long C, Kazura JW, Moormann AM. 2011. Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1. PLoS One 6:e24852. doi:10.1371/journal.pone.0024852.
41. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak DR, Asher TE, Douek DC, Harari A, Pantaleo G, Bailer R, Graham BS, Roederer M, Koup RA. 2007. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp. Med. 204:1405-1416.
42. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP. 2011. A human memory T cell subset with stem cell-like properties. Nat. Med. 17:1290-1297.
43. Moormann AM, Embury PE, Opondo J, Sumba OP, Ouma JH, Kazura JW, John CC. 2003. Frequencies of sickle cell trait and glucose-6-phosphate dehydrogenase deficiency differ in highland and nearby lowland malaria-endemic areas of Kenya. Trans. R. Soc. Trop. Med. Hyg. 97:513-514.
44. Hay SI, Smith DL, Snow RW. 2008. Measuring malaria endemicity from intense to interrupted transmission. Lancet Infect. Dis. 8:369-378.
45. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6:2743-2751.
46. Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, Oduor M, Munz C, Rochford R. 2009. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int. J. Cancer 124:1721-1726.
47. Greenwood BM, Bradley-Moore AM, Bryceson AD, Palit A. 1972. Immunosuppression in children with malaria. Lancet i:169-172.
48. Chene A, Donati D, Guerreiro-Cacais AO, Levitsky V, Chen Q, Falk KI, Orem J, Kironde F, Wahlgren M, Bejarano MT. 2007. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog. 3:e80. doi:10.1371/journal.ppat.0030080.
49. Piriou E, Kimmel R, Chelimo K, Middeldorp JM, Odada PS, Ploutz-Snyder R, Moormann AM, Rochford R. 2009. Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya. J. Med. Virol. 81:1088-1093.
50. Rahman MA, Kingsley LA, Atchison RW, Belle S, Breinig MC, Ho M, Rinaldo CR, Jr. 1991. Reactivation of Epstein-Barr virus during early infection with human immunodeficiency virus. J. Clin. Microbiol. 29: 1215-1220.
51. de The G, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, Smith PG, Dean AG, Bronkamm GW, Feorino P, Henle W. 1978. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 274:756-761.
52. Geser A, de The G, Lenoir G, Day NE, Williams EH. 1982. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int. J. Cancer 29:397-400.
53. Franklin BS, Parroche P, Ataide MA, Lauw F, Ropert C, de Oliveira RB, Pereira D, Tada MS, Nogueira P, da Silva LH, Bjorkbacka H, Golenbock DT, Gazzinelli RT. 2009. Malaria primes the innate immune response due to interferon-gamma induced enhancement of Toll-like receptor expression and function. Proc. Natl. Acad. Sci. U. S. A. 106:5789-5794.
54. McCall MB, Netea MG, Hermsen CC, Jansen T, Jacobs L, Golenbock D, van der Ven AJ, Sauerwein RW. 2007. Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J. Immunol. 179:162-171.